Kenvue Inc. (NYSE:KVUE) Shares Acquired by Brooklyn Investment Group

Brooklyn Investment Group boosted its holdings in Kenvue Inc. (NYSE:KVUE) by 37.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,243 shares of the company’s stock after purchasing an additional 1,152 shares during the quarter. Brooklyn Investment Group’s holdings in Kenvue were worth $91,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. FMR LLC increased its stake in shares of Kenvue by 2.3% during the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company’s stock valued at $3,189,985,000 after acquiring an additional 3,075,019 shares during the last quarter. State Street Corp boosted its holdings in shares of Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after purchasing an additional 18,283,473 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Kenvue by 8.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after buying an additional 7,115,374 shares during the period. Geode Capital Management LLC increased its holdings in shares of Kenvue by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company’s stock worth $1,029,810,000 after buying an additional 399,846 shares during the last quarter. Finally, Harris Associates L P raised its position in shares of Kenvue by 7.5% in the 3rd quarter. Harris Associates L P now owns 31,459,511 shares of the company’s stock worth $727,658,000 after buying an additional 2,186,114 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Trading Down 0.4 %

Shares of KVUE opened at $21.11 on Monday. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The stock has a 50-day moving average price of $22.42 and a 200 day moving average price of $21.71. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market capitalization of $40.46 billion, a P/E ratio of 38.37, a P/E/G ratio of 1.99 and a beta of 1.46.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business’s revenue was down .4% on a year-over-year basis. During the same period in the prior year, the business posted $0.31 EPS. Sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.89%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s payout ratio is currently 149.09%.

Analyst Ratings Changes

Several equities research analysts have commented on KVUE shares. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. UBS Group dropped their target price on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday. Bank of America lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Citigroup dropped their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Finally, Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $21.00 to $26.00 in a report on Monday, January 6th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $23.08.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.